The company said it will seek an expanded indication for the left atrial appendage closure device after it met all safety and ...

CHAMPION-AF shows Boston Scientific's Watchman FLX as a safe, effective first-line option for stroke risk reduction in ...

In one of the largest studies of its kind, a trial of Boston Scientific’s small, permanent cardiac implant showed that it could potentially serve as an alternative to long-term blood thin | Boston ...

Boston Scientific Corporation (NYSE: BSX) today announced that the CHAMPION-AF global clinical trial met all primary and ...

The study evaluated the company’s Watchman FLX device, designed to reduce stroke risk in patients with non valvular atrial ...

Data for Boston Scientific’s Watchman FLX implant met the primary endpoint in a new study. The stock is falling anyway.

Study suggests a path forward for device therapy, though caveats are plenty ...

S&P 500 slipped 0.39% to finish Monday at 6,344, while the Nasdaq Composite declined 0.73% to close at 20,795. Among medical device peers, Medtronic closed at $85.78 (-1.56%) and Stryker ended at $326 ...

Physicians wrestled with endpoint composition, low event rates, a possible difference in ischemic strokes, and more.

For patients with nonvalvular atrial fibrillation (AFib) who had no contraindications to taking oral anticoagulants, the use ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

For patients with non-valvular atrial fibrillation (AFib) who had no contraindications to taking oral anticoagulants, the use of a device to close off the left atrial appendage in the heart—a small ...